WO2006138744A2 - Derives d'heteroaryle utilises dans le traitement des virus - Google Patents

Derives d'heteroaryle utilises dans le traitement des virus Download PDF

Info

Publication number
WO2006138744A2
WO2006138744A2 PCT/US2006/024554 US2006024554W WO2006138744A2 WO 2006138744 A2 WO2006138744 A2 WO 2006138744A2 US 2006024554 W US2006024554 W US 2006024554W WO 2006138744 A2 WO2006138744 A2 WO 2006138744A2
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
cyclohexyl
quinolin
alkyl
heterocyclic
Prior art date
Application number
PCT/US2006/024554
Other languages
English (en)
Other versions
WO2006138744A3 (fr
Inventor
Franz Ulrich Schmitz
Janos Botyanszki
Christopher Don Roberts
Original Assignee
Genelabs Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Technologies, Inc. filed Critical Genelabs Technologies, Inc.
Priority to CA002613261A priority Critical patent/CA2613261A1/fr
Priority to AU2006261132A priority patent/AU2006261132A1/en
Priority to EP06799960A priority patent/EP1910337A2/fr
Priority to BRPI0612124-1A priority patent/BRPI0612124A2/pt
Priority to JP2008518457A priority patent/JP2008546802A/ja
Priority to MX2007016144A priority patent/MX2007016144A/es
Publication of WO2006138744A2 publication Critical patent/WO2006138744A2/fr
Publication of WO2006138744A3 publication Critical patent/WO2006138744A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the invention relates to the field of pharmaceutical chemistry, in particular to compounds, compositions and methods for treating viral infections in mammals mediated, at least in part, by a virus in the Flaviviridae family of viruses.
  • Chronic infection with HCV is a major health problem associated with liver cirrhosis, hepatocellular carcinoma and liver failure.
  • An estimated 170 million chronic carriers worldwide are at risk of developing liver disease. 1 ' 2
  • In the United States alone 2.7 million are chronically infected with HCV, and the number of HCV-related deaths in 2000 was estimated between 8,000 and 10,000, a number that is expected to increase significantly over the next years.
  • Infection by HCV is insidious in a high proportion of chronically infected (and infectious) carriers who may not experience clinical symptoms for many years.
  • Liver cirrhosis can ultimately lead to liver failure.
  • Liver failure resulting from chronic HCV infection is now recognized as a leading cause of liver transplantation.
  • HCV is a member of the Flaviviridae family of RNA viruses that affect animals and humans.
  • the genome is a single ⁇ 9.6-kilobase strand of RNA, and consists of one open reading frame that encodes for a polyprotein of ⁇ 3000 amino acids flanked by untranslated regions at both 5' and 3' ends (5'- and 3'-UTR).
  • the polyprotein serves as the precursor to at least 10 separate viral proteins critical for replication and assembly of progeny viral particles.
  • the organization of structural and non-structural proteins in the HCV polyprotein is as follows: C-El-E2-p7-NS2-NS3-NS4a-NS4b-NS5a-NS5b.
  • HCV infection can theoretically be cured. While the pathology of HCV infection affects mainly the liver, the virus is found in other cell types in the body including peripheral blood lymphocytes. 3 ' 4
  • IFN-alpha interferon alpha
  • ribavirin the standard treatment for chronic HCV.
  • IFN-alpha belongs to a family of naturally occurring small proteins with characteristic biological effects such as antiviral, immunoregulatory and antitumoral activities that are produced and secreted by most animal nucleated cells in response to several diseases, in particular viral infections.
  • IFN-alpha is an important regulator of growth and differentiation affecting cellular communication and immunological control.
  • NS3/4a protease/helicase and the NS 5b RNA-dependent RNA polymerase are considered the most promising viral targets
  • antiviral activity can also be achieved by targeting host cell proteins that are necessary for viral replication.
  • Watashi et al. 9 show how antiviral activity can be achieved by inhibiting host cell cyclophilins.
  • a potent TLR7 agonist has been shown to reduce HCV plasma levels in humans. 10
  • the present invention is directed to novel compounds, compositions, and methods for treating of viral infections in mammals mediated, at least in part, by a member of the
  • Flaviviridae family viruses such as HCV. Specifically, compounds of this invention are represented by formula (1):
  • L is selected from the group consisting of a bond, C 1 -C 3 alkylene, substituted C 1 -C 3 alkylene, C 2 -C 3 alkenylene, substituted C 2 -C 3 alkenylene, C 2 -C 3 alkynylene, substituted C 2 -C 3 alkynylene, C 3 -C 6 cycloalkylene, substituted C 3 -C 6 cycloalkylene, C 4 -C 6 cycloalkenylene, C 4 -C 6 substituted cycloalkenylene, arylene, substituted arylene, heteroarylene, and substituted heteroarylene; one of X or X' is N-R 1 and the other is selected from the group consisting of C-R 2 , N, O or S;
  • Q is selected from the group consisting of C-R, N, O or S with the proviso that when X or X' is O or S, then Q is selected from C-R and N;
  • R is selected from the group consisting of hydrogen, halo, C 1 -C 2 alkyl, substituted C 1 -C 2 alkyl, C 2 -C 3 alkenyl, substituted C 2 -C 3 alkenyl, cyclopropyl, and substituted cyclopropyl;
  • R 1 and R 2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, cycloalkenyl, substituted cycloalkenyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, -COOH, -COOR la , -CH 2 CONR 3 R 4 , and -NR 3 R 4 ; where each of R la , R 3 and R 4 is independently selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; or,
  • R 13 and R 13 are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; or, alternatively, R 13 and R 13' as defined are taken together with the carbon atom pendent thereto to form a cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic group; or, still further alternatively, one of R 13 or R 13 is hydrogen, alkyl or substituted alkyl, and the other is joined, together with the carbon atom pendent thereto, with either the R 16 and the oxygen atom pendent thereto or R 10 and the nitrogen atom pendent thereto to form a heterocyclic or substituted heterocyclic group; R 12 is selected from hydrogen and alkyl or, when R 13
  • R 18 and R 19 are independently alkyl, substituted alky, aryl, substituted aryl, heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl, or R 17 and R 18 together with the carbon atom pendent thereto form a cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic group; and (g) carboxylic acid isostere; with the proviso that when L is a bond, Z is not hydrogen;
  • Het is selected from the group consisting of arylene, substituted arylene, heteroarylene and substituted heteroarylene;
  • Y is selected from the group consisting of alkyl, aryl, heteroaryl, substituted aryl, and substituted heteroaryl; or a pharmaceutically acceptable salt, ester, stereoisomer, prodrug, or tautomer thereof.
  • the invention is directed to compounds, compositions and methods for treating Flaviviridae family viral infections.
  • the present invention provides compounds represented by formula (I):
  • L is selected from the group consisting of a bond, C 1 -C 3 alkylene, substituted C 1 -C 3 alkylene, C 2 -C 3 alkenylene, substituted C 2 -C 3 alkenylene, C 2 -C 3 alkynylene, substituted C 2 -C 3 alkynylene, C 3 -C 6 cycloalkylene, substituted C 3 -C 6 cycloalkylene, C 4 -C 6 cycloalkenylene, C 4 -C 6 substituted cycloalkenylene, arylene, substituted arylene, heteroarylene, and substituted heteroarylene; one of X or X' is N-R 1 and the other is selected from the group consisting of C-R 2 , N, O or S;
  • Q is selected from the group consisting of C-R, N, O or S with the proviso that when X or X' is O or S, then Q is selected from C-R and N;
  • R is selected from the group consisting of hydrogen, halo, C 1 -C 2 alkyl, substituted
  • R 1 and R 2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, cycloalkenyl, substituted cycloalkenyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, -COOH, -COOR la , -CH 2 CONR 3 R 4 , and -NR 3 R 4 ; where each of R la , R 3 and R 4 is independently selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; or,
  • Z is selected from the group consisting of: (a) hydrogen, halo, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, cyano, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, and substituted amino;
  • R z is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
  • R 13 and R 13 are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; or, alternatively, R 13 and R 13 as defined are taken together with the carbon atom pendent thereto to form a cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic group; or, still further alternatively, one of R 13 or R 13 is hydrogen, alkyl or substituted alkyl, and the other is joined, together with the carbon atom pendent thereto, with either the R 16 and the oxygen atom pendent thereto or R 10 and the nitrogen atom pendent thereto to form a heterocyclic or substituted heterocyclic group;
  • R 12 is selected from hydrogen and alkyl or, when R 13 and R 13 are not taken together to form a ring and when R 13 or R 13 and R 10 or R 11 are not joined to form a heterocyclic or substituted heterocyclic group, then R 12 , together with the nitrogen atom pendent thereto, may be taken together with one of R 13 and R 13 to form a heterocyclic or substituted heterocyclic ring group; (f) -C(X 2 )-N(R 12 )CR 17 R 18 R 19 , wherein X 2 and R 12 are defined above, and R 17 , R 18 and R 19 are independently alkyl, substituted alky, aryl, substituted aryl, heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl, or R 17 and R 18 together with the carbon atom pendent thereto form a cycloalkyl, substituted cycloalkyl, heterocyclic or substituted heterocyclic group; and
  • Het is selected from the group consisting of arylene, substituted arylene, heteroarylene and substituted heteroarylene; and Y is selected from the group consisting of alkyl, aryl, heteroaryl, substituted aryl, and substituted heteroaryl; or a pharmaceutically acceptable salt, ester, stereoisomer, prodrug, or tautomer thereof.
  • the present invention is directed to compounds of formula (I) having formulae (II), (III), and (IV) or the pharmaceutically acceptable salt, ester, stereoisomer, prodrug, or tautomer thereof:
  • the present invention provides compounds of formula (V) or a pharmaceutically acceptable salt, ester, stereoisomer, prodrug, or tautomer thereof:
  • T 1 is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, cyano, carboxyl, carboxyl ester, halo, hydroxy, heterocyclic, substituted hetereocyclic, and nitro; and n is an integer equal to 0, 1, or 2.
  • the invention provides compounds of formula (I)
  • the invention provides compounds of formula (I)
  • the invention provides compounds of formula (I) - (V) where L is a bond.
  • the invention provides compounds of formula (I) - (V) where L is a heteroarylene or a substituted heteroarylene.
  • L is a heteroarylene or a substituted heteroarylene.
  • Z-L- form a group having the formula:
  • V 1 , V 2 , and V 3 are independently selected from the group consisting of O, S, N, NH, or CH.
  • Z is COOH.
  • V , V , and V have one of the following combinations:
  • V 1 is CH, V 2 is NH, and V 3 is CH; V 1 is NH, V 2 is CH, and V 3 is CH; V 1 is CH, V 2 is CH, and V 3 is N; V 1 is CH, V 2 is NH, and V 3 is N; V 1 is NH 5 V 2 is CH 5 and V 3 is N; V 1 is NH, V 2 is N, and V 3 is CH; V 1 is NH, V 2 is N s and V 3 is N; V 1 is CH, V 2 is O, and V 3 is CH;
  • V 1 is CH 5 V 2 is CH, and V 3 is O; V 1 is CH, V 2 is S, and V 3 is CH; V 1 is CH, V 2 is CH, and V 3 is S; V 1 is CH, V 2 is O 5 and V 3 is N; V 1 is CH 5 V 2 is N, and V 3 is O;
  • V 1 is CH, V 2 is S, and V 3 is N; or V 1 is CH, V 2 is N, V 3 is S.
  • the invention provides compounds of formula (I) - (V) where Het is heteroarylene or substituted heteroarylene, Y is aryl, heteroaryl, substituted aryl, or substituted heteroaryl, and Het and Y together form a
  • -Het-Y group has the formula (Hl)
  • each of W 1 , W 2 , W 3 and W 4 is independently selected from N, CH 5 CT 2 , and C-Y 5 provided that no more than 2 of W 1 , W 2 , W 3 and W 4 are N; provided that one of W 1 , W 2 5 W 3 and W 4 is C-Y; and further provided wherein no more than one N in the ring system is optionally oxidized to form the N-oxide.
  • T 1 and T 2 are independently selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, cyano, carboxyl, carboxyl ester, halo, hydroxy, heterocyclic, substituted hetereocyclic, and nitro; and n is an integer equal to O, I 5 or 2.
  • said -Het-Y group has the formula (H2) where T 1 , n, and Y are defined as for formula (Hl).
  • the invention provides compounds of formula (I)
  • Y is heteroaryl or substituted heteroaryl.
  • Y is tbiazole-5-yl or 2,4-dimethylthiazol-5-yl.
  • the invention provides compounds of formula (I)
  • the invention provides compounds of formula (I) (V) where R 1 or R 2 is selected from the group consisting of -COOH 5 -CH 2 C00R la , and
  • R .1 o _r ⁇ R2 when said R .1 o _r ⁇ R2 is attached to a ring atom adjacent to a ring atom bearing L.
  • R 3 and R 4 together with the nitrogen to which they are attached, form a morpholino ring.
  • the invention provides compounds of formula (I) - (V) where R 1 or R 2 is cyclohexyl when said R 1 or R 2 is attached to a ring atom adjacent to a ring atom bearing R.
  • the present invention further provides compounds resulting from a combination of any of the variables relating to the atoms and substituents of formula (I) - (V), particularly those variables in the preferred embodiments above.
  • Preferred compounds of this invention resulting form such combinations include, by way of example, those set forth in Table I below and their pharmaceutically acceptable salt, ester, stereoisomer, prodrug, or tautomer thereof.
  • alkynyl compounds corresponding to compounds 1-20 and 24-29 wherein the alkenylene group L is replaced with an alkynylene group.
  • compositions comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of one of the compounds described herein or mixtures of one or more of such compounds.
  • This invention is further directed to uses of the compounds as described herein or mixtures of one or more of such compounds in the preparation of a medicament for treating a viral infection mediated, at least in part, by a virus in the Flaviviridae family of viruses, such as HCV.
  • This invention is still further directed to methods for treating a viral infection mediated at least in part by a virus in the flaviviridae family of viruses, such as HCV, in mammals which methods comprise administering to a mammal, that has been diagnosed with said viral infection or is at risk of developing said viral infection, a pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of one of the compounds described herein or mixtures of one or more of such compounds.
  • agents active against HCV include ribavirin, levovirin, viramidine, thymosin alpha- 1, an inhibitor of NS3 serine protease, and inhibitor of inosine monophosphate dehydrogenase, interferon-alpha, pegylated interferon-alpha, alone or in combination with ribavirin or viramidine.
  • the additional agent active against HCV is interferon-alpha or pegylated interferon-alpha alone or in combination with ribavirin or viramidine.
  • alkyl refers to monovalent hydrocarbyl groups having from 1 to 10 carbon atoms, preferably from 1 to 5 carbon atoms, more preferably 1 to 3 carbon atoms, and also more preferably from 1 to 2 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, wo-propyl, r ⁇ -butyl, t-butyl, «-pentyl and the like.
  • Substituted alkyl refers to an alkyl group having from 1 to 3, and preferably 1 to 2, substituents selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxy, nitro, carboxy, carboxy ester, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.
  • Alkoxy refers to the group “alkyl-O-" which includes, by way of example, methoxy, ethoxy, «-propoxy, w ⁇ -propoxy, n-butoxy, t-butoxy, sec-butoxy, r ⁇ -pentoxy and the like.
  • Substituted alkoxy refers to the group “substituted alkyl-O-”.
  • Acyl refers to the groups H-C(O)-, alkyl-C(O)-, substituted alkyl-C(O)-, alkenyl-C(O)-, substituted alkenyl-C(O)-, alkynyl-C(O)-, substituted alkynyl-C(O)-, cycloalkyl-C(O)-, substituted cycloalkyl-C(O)-, aryl-C(O)-, substituted aryl-C(O)-, heteroaryl-C(O)-, substituted heteroaryl-C(O), heterocyclic-C(O)-, and substituted heterocyclic-C(O)-.
  • Acylamino refers to the group -C(O)NR f R g where R f and R g> is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where R f and R s are joined to form together with the nitrogen atom a heterocyclic or substituted heterocyclic ring.
  • Acyloxy refers to the groups alkyl-C(O)O-, substituted alkyl-C(O)O-, alkenyl-C(O)O-, substituted alkenyl-C(0)O, alkynyl-C(O)O-, substituted alkynyl-C(O)O- 5 aryl-C(O)O-, substituted aryl-C(O)O-, cycloalkyl-C(O)O-, substituted cycloalkyl-C(O)O-, heteroaryl-C(O)O-, substituted heteroaryl-C(O)O-, heterocyclic-C(O)O-, and substituted heterocyclic-C(O)O-.
  • Alkenyl refers to hydrocarbyl groups having from 2 to 10 carbon atoms, preferably having from 2 to 6 carbon atoms, and more preferably 2 to 4 carbon atoms and having at least 1 and preferably from 1-2 sites of alkenyl unsaturation wherein each site of unsaturation independently has either cis or trans orientation or a mixture thereof.
  • Substituted alkenyl refers to alkenyl groups having from 1 to 3 substituents, and preferably 1 to 2 substituents, selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxy, nitro, carboxy, carboxy ester, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic provided that any hydroxyl substitution is not pendent to a vinyl carbon atom.
  • Alkenylene and “substituted alkenylene” refer to divalent alkenyl and substituted alkenyl groups as defined above. Preferred alkenylene and substituted alkenylene groups have two to three carbon atoms.
  • alkenyloxy refers to the group alkenyl-O-.
  • Alkylaryloxy refers to the group alkyl-arylene-O-.
  • Alkylthio refers to the group alkyl-S-.
  • Alkyloxy refers to the group aryl-alkylene-0-.
  • Alkynyl refers to hydrocarbyl groups having from 2 to 10 carbon atoms, preferably having from 2 to 6 carbon atoms, and more preferably 2 to 3 carbon atoms and having at least 1 and preferably from 1-2 sites of alkynyl unsaturation.
  • Substituted alkynyl refers to alkynyl groups having from 1 to 3 substituents, and preferably 1 to 2 substituents, selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxy, nitro, carboxy, carboxy ester, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic provided that any hydroxyl substitution is not pendent to an acetylenic carbon atom.
  • Alkynylene and substituted alkynylene refer to divalent alkynyl and substituted alkynyl groups as defined above. Preferred alkynlene and substituted alkynylene groups have two to three carbon atoms.
  • Alkylene and substituted alkylene refer to divalent alkyl and substituted alkyl groups as defined above. Preferred alkylene and substituted alkylene groups have one to three or two to three carbon atoms.
  • Amino refers to the group -NH 2 .
  • Substituted amino refers to the group -NR h R 1 where R h and R 1 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where R h and R 1 are joined, together with the nitrogen bound thereto to form a heterocyclic or substituted heterocyclic group provided that R h and R 1 are both not hydrogen.
  • R h is hydrogen and R 1 is alkyl
  • the substituted amino group is sometimes referred to herein as alkylamino.
  • R h and R 1 are alkyl
  • the substituted amino group is sometimes referred to herein as dialkylamino.
  • Aminoacyl refers to the groups -NR j' C(O)alkyl, -NR j' C(O)substituted alkyl, -NR j' C(O)-cycloalkyl, -NR j> C(O)substituted cycloalkyl, -NR j' C(O)alkenyl, -NR j' C(O)substituted alkenyl, -NR j' C(O)alkynyl, -NR j' C(O)substituted alkynyl, -NR j' C(O)aryl, -NR j' C(O)substituted aryl, -NR j> C(O)heteroaryl, -NR j' C(O)substituted heteroaryl, -NR* C(O)heterocyclic, and -NR J C(O)substituted heterocyclic where
  • aminoalkyl refers to the group amino-alkyl-.
  • Aryl or “Ar” refers to a monovalent aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic (e.g., 2- benzoxazolinone, 2H-l,4-benzoxazin-3(4H)-one-7-yl, and the like) provided that the point of attachment is to an aromatic ring atom.
  • Preferred aryls include phenyl and naphthyl.
  • Substituted aryl refers to aryl groups which are substituted with from 1 to 3 substituents, and preferably 1 to 2 substituents, selected from the group consisting of hydroxy, acyl, acylamino, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cycloalkoxy, substituted cycloalkoxy, carboxy, carboxy esters, cyano, thiol, cycloalkyl, substituted cycloalkyl, halo, nitro, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, and substituted heterocyclyloxy.
  • Alkyl or “arylalkyl” refers to the group aryl-alkyl-.
  • Arylene and “substituted arylene” refer to divalent aryl and substituted aryl groups as defined above.
  • Aryloxy refers to the group aryl-O- that includes, by way of example, phenoxy, naphthoxy, and the like.
  • Substituted aryloxy refers to substituted aryl-O- groups.
  • Carboxy or “carboxyl” refers to -COOH or salts thereof.
  • Carboxy esters or “carboxyl esters” refers to the groups -C(O)O-alkyl, -C(O)O-substituted alkyl, -C(O)O-alkenyl, -C(O)O-substituted alkenyl, -C(O)O-alkynyl, -C(O)O-substituted alkynyl, -C(O)O-aryl, -C(O)O-substituted aryl, -C(O)O-heteroaryl, -C(O)O-substituted heteroaryl, -C(O)O-heterocyclic, and -C(O)O-substituted heterocyclic.
  • carboxy esters are -C(O)O-alkyl, -C(O)O-substituted alkyl, -C(O)O-aryl, and -C(O)O-substituted aryl.
  • Cycloalkyl refers to cyclic alkyl groups of from 3 to 10 carbon atoms having single or multiple cyclic rings optionally comprising 1 to 3 exo carbonyl or thiocarbonyl groups.
  • Suitable cycloalkyl groups include, by way of example, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, 3-oxocyclohexyl, and the like.
  • one or more of the rings may be other than cycloalkyl (e.g., aryl, heteroaryl or heterocyclic) provided that the point of attachment is to a carbon ring atom of the cycloalkyl group.
  • Substituted cycloalkyl refers to a cycloalkyl group, having from 1 to 5 substituents selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxy, nitro, carboxy, carboxy esters, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.
  • the cycloalkyl group does not comprise 1 to 3 exo carbonyl or thiocarbonyl groups. In another embodiment, the cycloalkyl group does comprise 1 to 3 exo carbonyl or thiocarbonyl groups. It is understood, that the term "exo" refers to the attachment of a carbonyl or thiocarbonyl to a carbon ring atom of the cycloalkyl group. Substituted cyclopropyl is a species of substituted cycloalkyl and refers to a C 3 cycloalkyl substituted as above.
  • Cycloalkenyl refers to cyclic alkenyl but not aromatic groups of from 4 to 10 carbon atoms having single or multiple cyclic rings. Suitable cycloalkenyl groups include, by way of example, cyclopentyl, cyclohexenyl, and cyclooctenyl. In multiple condensed rings, one or more of the rings may be other than cycloalkenyl (e.g., aryl, heteroaryl or heterocyclic) provided that the point of attachment is to a carbon ring atom of the cycloalkyl group.
  • Substituted cycloalkenyl refers to cycloalkenyl groups, having from 1 to 5 substituents selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxy, nitro, carboxy, carboxy esters, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic provided that for hydroxyl substituents the point of attachment is not to a vinyl carbon atom.
  • Substituted cycloalkenyl also refers to cycloalkenyl groups optionally comprising 1 to 3 exo carbonyl or thiocarbonyl groups. It is understood, that the term “exo” refers to the attachment of a carbonyl or thiocarbonyl to a carbon ring atom of the cycloalkenyl group. Suitable 3-oxocyclohexenyl, and the like. In one embodiment, the cycloalkenyl group does not comprise 1 to 3 exo carbonyl or thiocarbonyl groups. In another embodiment, the cycloalkenyl group does comprise 1 to 3 exo carbonyl or thiocarbonyl groups.
  • Cycloalkylene and substituted cycloalkylene refer to divalent cycloalkyl and substituted cycloalkyl groups as defined above. Preferred cycloalkylene and substituted cycloalkylene groups have three to six carbon atoms.
  • Cycloalkenylene and substituted cycloalkenylene refer to divalent cycloalkenyl and substituted cycloalkenyl groups as defined above. Preferred cycloalkenylene and substituted cycloalkenylene groups have four to six carbon atoms.
  • Cycloalkoxy refers to -O-cycloalkyl groups.
  • Substituted cycloalkoxy refers to -O-substituted cycloalkyl groups.
  • Halo or halogen refers to fluoro, chloro, bromo and iodo and preferably is fluoro or chloro.
  • Hyalkyl refers to an alkyl group substituted with 1 to 10 halogen atoms.
  • Heteroaryl refers to an aromatic group of from 1 to 15 carbon atoms, preferably from 1 to 10 carbon atoms, and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, within the ring.
  • such heteroaryl groups are aromatic groups of from 1 to 15 carbon atoms, preferably from 1 to 10 carbon atoms, and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur within the ring.
  • heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl).
  • the sulfur atom(s) in the heteroaryl group may optionally be oxidized to sulfoxide and sulfone moieties.
  • Substituted heteroaryl 1 ' refers to heteroaryl groups that are substituted with from 1 to 3 substituents selected from the same group of substituents defined for substituted aryl.
  • substituted heteroaryl e.g., substituted qunioline, it is understood that such a heteroaryl contains the 1 to 3 substituents as recited above.
  • Heteroarylene and “substituted heteroarylene” refer to divalent heteroaryl and substituted heteroaryl groups as defined above.
  • Heteroaryloxy refers to the group -O-heteroaryl and “substituted heteroaryloxy” refers to the group -O-substituted heteroaryl.
  • Heterocycle or “heterocyclic” refers to a saturated or unsaturated non-aromatic group having a single ring or multiple condensed rings, from 1 to 10 carbon atoms and from 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur or oxygen within the ring which ring may optionally comprise 1 to 3 exo carbonyl or thiocarbonyl groups.
  • heterocyclic groups are saturated or unsaturated group having a single ring or multiple condensed rings, from 1 to 10 carbon atoms and from 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur, or oxygen within the ring.
  • the sulfur atom(s) in the heteroaryl group may optionally be oxidized to sulfoxide and sulfone moieties.
  • one or more of the rings may be other than heterocyclic (e.g., aryl, heteroaryl or cycloalkyl) provided that the point of attachment is to a heterocyclic ring atom.
  • the heterocyclic group does not comprise 1 to 3 exo carbonyl or thiocarbonyl groups.
  • the heterocyclic group does comprise 1 to 3 exo carbonyl or thiocarbonyl groups. It is understood, that the term "exo" refers to the attachment of a carbonyl or thiocarbonyl to a carbon ring atom of the heterocyclic group.
  • Substituted heterocyclic refers to heterocycle groups that are substituted with from 1 to 5 of the same substituents as defined for substituted cycloalkyl.
  • Preferred substituents for substituted heterocyclic groups include heterocyclic groups having from 1 to 3 substituents selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxy, nitro, carboxy, carboxy esters, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.
  • substituted e.g., substituted morpholino
  • heterocycles and heteroaryls include, but are not limited to, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, dihydroindole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, phthalimide, 1,2,3,4-tetrahydro-isoquinolme, 4,5,6,7-t
  • Heterocyclyloxy refers to the group -O-heterocyclic and “substituted heterocyclyloxy” refers to the group -O-substituted heterocyclic.
  • Hydrophilyloxy or “hydroxyl” refers to -OH.
  • Sulfonyl refers to the group -SO 2 -.
  • Thiol refers to the group -SH.
  • Thioalkyl refers to the group HS-alkyl-.
  • amino acid refers to ⁇ -amino acids or to ⁇ -amino acids of the formula HR b N[CH(R a' )] c 'COOH where R a> is an amino acid side chain, R b> is hydrogen, alkyl, substituted alkyl or aryl and c ' is one or two.
  • c ' is one, an ⁇ -amino acid, and the ⁇ -amino acid is one of the twenty naturally occurring L amino acids.
  • Isosteres are different compounds that have different molecular formulae but exhibit the same or similar properties.
  • tetrazole is an isostere of carboxylic acid because it mimics the properties of carboxylic acid even though they both have very different molecular formulae. Tetrazole is one of many possible isosteric replacements for carboxylic acid.
  • carboxylic acid isosteres contemplated by the present invention include -COOH 5 -SO 3 H 5 -S0 2 HNR k> , -PO 2 (R k> ) 2 , -CN 5 -PO 3 (R k' ) 2 , -OR k , -SR k> , -NHC0R k> 5 -N(R k' ) 2 , -C0N(R k> ) 2 , -CONH(O)R k' 5 -CONHNHSO 2 R k> 5 -COHNSO 2 R k' 5 and -CONR k CN, where R k is selected from hydrogen, hydroxy, halo, haloalkyl, thiocarbonyl, alkoxy, alkenoxy, alkylaryloxy, aryloxy, arylalkyloxy, cyano, nitro, imino, alkylamino, aminoalkyl, thiol
  • carboxylic acid isosteres can include 5-7 membered carbocycles or heterocycles containing any combination OfCH 2 , O 5 S 5 or N in any chemically stable oxidation state, where any of the atoms of said ring structure are optionally substituted in one or more positions.
  • the following structures are non-limiting examples of preferred carboxylic acid isosteres contemplated by this invention.
  • Carboxylic acid bioisosteres are compounds that behave as isosteres of carboxylic acids under biological conditions.
  • “Pharmaceutically acceptable salt” refers to pharmaceutically acceptable salts of a compound, which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
  • Prodrug refers to any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention that is capable of directly or indirectly providing a compound of this invention or an active metabolite or residue thereof when administered to a subject.
  • Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a subject (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.
  • Prodrugs include ester forms of the compounds of the invention.
  • ester prodrugs include formate, acetate, propionate, butyrate, acrylate, and ethylsuccinate derivatives.
  • An general overview of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.
  • impermissible substitution patterns e.g., methyl substituted with 5 fluoro groups or a hydroxy group alpha to ethenylic or acetylenic unsaturation.
  • impermissible substitution patterns are well known to the skilled artisan.
  • the compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
  • protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions.
  • Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and P. G. M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley, New York, 1999, and references cited therein. If the compounds of this invention contain one or more chiral centers, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures.
  • stereoisomers and enriched mixtures are included within the scope of this invention, unless otherwise indicated.
  • Pure stereoisomers may be prepared using, for example, optically active starting materials or stereoselective reagents well- known in the art.
  • racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents and the like.
  • Scheme 1 employs the following substitution patterns: X is NR 1 where R 1 is methylenecarboxyl, methylene carboxylate or a 2-(2-morpholin-4-yl-2-oxoeth-lyl); Q is CH; X' is C-R 2 where R 2 is cyclohexyl; L is a bond; Z is carboxyl, carboxylate or an amide derived from reaction with the amino group of an amino acid (e.g., glycine); Het is quinolin-2,6-ylene and Y is 2,4-dimethylthiazol-5-yl.
  • Other compounds and substitution patterns can readily be made by the following the procedures below with proper substitution of reagents. Such factors are well within the skill of the art.
  • compound IB 2,2,2-trichloro-l-(4-bromo-lH- pyrrol-2-yl)-ethanone
  • 2,2,2-Trichloro-l-(4-bromo-lH-pyrrol-2-yl)-ethanone, compound IB is contacted with sodium methoxide to effect conversion to the methyl ester, compound 1 C.
  • This reaction proceeds by contacting compound IB with an excess of sodium methoxide, typically from 1.1 to 5 equivalents and preferably 1.5 equivalents, in a suitable diluent such as methanol. The reaction is continued until it is substantially complete which typically occurs within about 1 to 30 minutes.
  • compound 1C methyl 4-bromo-lH-pyrrole-2-carboxylate
  • Alkylation of the pyrrole amine of compound 1C proceeds via reaction with bromoacetic acid t-butyl ester.
  • compound 1C is contacted with an excess of a suitable base such sodium hydride in a suitable solvent such as DMF to facilitate the subsequent nucleophilic displacement reaction.
  • a slight excess of an ⁇ - bromoacetic acid ester e.g. t-butyl bromoacetate, is added to the reaction mixture and the reaction is maintained under ambient conditions until substantial completion which typically occurs within about 1 to 30 minutes.
  • compound ID can be recovered by conventional methods including neutralization, evaporation, extraction, precipitation, chromatography, filtration, and the like or, alternatively, is employed in the next step without purification and/or isolation.
  • R 2 cyclohexyl group proceeds from compound ID with in situ generated zincate IE in the presence of Pd(P(tBu)3) 2 .
  • In situ formation of the zincate preferably proceeds by contacting approximately equivalent amounts of cyclohexyl- magnesium chloride and zinc chloride in an inert solvent such as THF. The reaction is at ambient temperature for about 0.1 to 1 hours followed by addition of a higher boiling solvent such as NMP. To this mixture is added compound ID and a slight excess of Pd(P(tBu) 3 ) 2 . The. reaction mixture is maintained under elevated temperature conditions, typically from about 80° to 120°C, until substantial completion which typically occurs within about 0.2 to 2 hours.
  • compound IF can be recovered by conventional methods including neutralization, evaporation, extraction, precipitation, chromatography, filtration, and the like or, alternatively, is employed in the next step without purification and/or isolation.
  • Bromination of compound IF proceeds under conventional conditions in the presence of pyridium tribromide to provide for compound IG.
  • Suzuki coupling of compound IG with an excess of boronic acid IH provides for compound IJ which can be recovered by conventional methods including neutralization, evaporation, extraction, precipitation, chromatography, filtration, and the like or, alternatively, is employed in the next step without purification and/or isolation.
  • Further functionalization of compound U using standard synthetic transformations provides for compounds IK, IL, and 10.
  • conventional deesterification provides for compound IK.
  • Selective deprotection of the t-butyl ester followed by reaction with morpholine provides for compound IM.
  • Further deesterification of compound IM provides for compound IN.
  • Conventional amino acid coupling to the carboxyl group of compound IN using, e.g., glycine provides for compound 10.
  • Scheme 2 A synthetic method for introducing an alkenylene linker is illustrated in Scheme 2. It is understood that for illustrative purposes, Scheme 2 employs the following substitution patterns: X is NR 1 where R 1 is 2-(2-morpholin-4-yl-2-oxoeth-lyl); Q is CH; X' is C-R where R is cyclohexyl; L is vinyl (E isomer); Z is carboxyl; Het is quinolin- 2,6-ylene and Y is 2,4-dimethylthiazol-5-yl. Other compounds and substitution patterns can readily be made by the following the procedures below with proper substitution of reagents. Such factors are well within the skill of the art.
  • compound IM is reduced to the corresponding alcohol by a selective reducing agent (one which does not reduce the amide bond) such as lithium trW-butoxy aluminum hydride to provide for compound 2B.
  • a selective reducing agent such as lithium trW-butoxy aluminum hydride
  • compound 2C proceeds via contact with a suitable oxidizing agent such as manganese dioxide.
  • a suitable oxidizing agent such as manganese dioxide.
  • Wittig coupling using methyl (triphenylphosphoranyl-idene)acetate gives vinyl acetate 2D that can also be saponified to yield 2E.
  • Scheme 3 employs the following substitution patterns: X is NR 1 where R 1 is 2-(2-morpholin-4-yl-2-oxoeth-lyl); Q is CH; X' is C-R 2 where R 2 is cyclohexyl; Z is carboxyl; Het is quinolin-2,6-ylene and Y is 2,4- dimethylthiazol-5-yl.
  • substitution patterns can readily be made by following the procedures below with proper substitution of reagents. Such factors are well within the skill of the art.
  • the vinyl group of compound 2E (described above) is hydrogenated by conventional methods such as hydrogen over a palladium on carbon catalyst to provide for the ethylene linker of compound 3 A.
  • the vinyl group of compound 2E is 1,2 brominated under conventional conditions.
  • a suitable base such as potassium t-butoxide provides for compound 3B.
  • Scheme 4 employs the following substitution patterns: X is NR 1 where R 1 is 2-(2-morpholin-4-yl-2-oxoeth-lyl); Q is CH; X' is C-R 2 where R 2 is cyclohexyl; Z is carboxyl; Het is quinolin-2,6-ylene and Y is 2,4-dimethylthiazol-5-yl.
  • Other compounds and substitution patterns can readily be made by following the procedures below with proper substitution of reagents. Such factors are well within the skill of the art.
  • the vinyl of compound 2E can be converted to the corresponding cyclopropyl group by conventional methods such as by reacting the vinyl group with a carbenoid to provide compound 4B.
  • a Diels- Alder reaction on compound 2E would provide the cyclohexenyl derivative, compound 4A.
  • Scheme 5 A method for introducing a heteroarylene linker is shown in Scheme 5. It is understood that for illustrative purposes, Scheme 5 employs the following substitution patterns: X is NR 1 where R 1 is 2-(2-morpholin-4-yl-2-oxoeth-lyl); Q is CH; X' is C-R 2 where R 2 is cyclohexyl; Z is carboxyl; Het is quinolin-2,6-ylene and Y is 2,4- dimethylthiazol-5-yl. Other compounds and substitution patterns can readily be made by following the procedures below with proper substitution of reagents. Such factors are well within the skill of the art. Scheme 5
  • Compound 5C can be converted to acid 5D under Hantzsch pyrrole synthesis conditions. Accordingly, 5C is reacted with 3-oxo-propionic acid methyl ester CH 3 OC(O)CH 2 CHO in the presence of aqueous ammonia to form the methyl ester of 5D. Saponification of the ester with a base such as LiOH gives acid 5D.
  • the present invention provides novel compounds possessing antiviral activity, including Flaviviridae family viruses such as hepatitis C virus.
  • Flaviviridae family viruses such as hepatitis C virus.
  • the compounds of this invention inhibit viral replication by inhibiting the enzymes involved in replication, including RNA dependent RNA polymerase. They may also inhibit other enzymes utilized in the activity or proliferation of Flaviviridae viruses.
  • Compounds of this invention maybe used alone or in combination with other compounds to treat viruses.
  • the compounds of this invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities.
  • the actual amount of the compound of this invention, i.e., the active ingredient will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, and other factors.
  • the drug can be administered more than once a day, preferably once or twice a day.
  • Therapeutically effective amounts of compounds of the present invention may range from approximately 0.01 to 50 mg per kilogram body weight of the recipient per day; preferably about 0.1-25 mg/kg/day, more preferably from about 0.1 to 10 mg/kg/day. Thus, for administration to a 70 kg person, the dosage range would most preferably be about 7-70 mg per day.
  • compounds of this invention will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration.
  • routes e.g., oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration.
  • the preferred manner of administration is oral using a convenient daily dosage regimen that can be adjusted according to the degree of affliction.
  • Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.
  • Another preferred manner for administering compounds of this invention is inhalation.
  • the choice of formulation depends on various factors such as the mode of drug administration and bioavailability of the drug substance.
  • the compound can be formulated as liquid solution, suspensions, aerosol propellants or dry powder and loaded into a suitable dispenser for administration.
  • suitable dispenser for administration There are several types of pharmaceutical inhalation devices-nebulizer inhalers, metered dose inhalers (MDI) and dry powder inhalers (DPI).
  • MDI metered dose inhalers
  • DPI dry powder inhalers
  • Nebulizer devices produce a stream of high velocity air that causes the therapeutic agents (which are formulated in a liquid form) to spray as a mist that is carried into the patient's respiratory tract.
  • MDFs typically are formulation packaged with a compressed gas.
  • the device Upon actuation, the device discharges a measured amount of therapeutic agent by compressed gas, thus affording a reliable method of administering a set amount of agent.
  • DPI dispenses therapeutic agents in the form of a free flowing powder that can be dispersed in the patient's inspiratory air-stream during breathing by the device.
  • the therapeutic agent In order to achieve a free flowing powder, the therapeutic agent is formulated with an excipient such as lactose.
  • a measured amount of the therapeutic agent is stored in a capsule form and is dispensed with each actuation.
  • pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example, U.S. Pat. No.
  • 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules.
  • U.S. Patent No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.
  • compositions are comprised of in general, a compound of the present invention in combination with at least one pharmaceutically acceptable excipient.
  • Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the claimed compounds.
  • excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
  • Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like.
  • Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.
  • Preferred liquid carriers, particularly for injectable solutions include water, saline, aqueous dextrose, and glycols.
  • Compressed gases may be used to disperse a compound of this invention in aerosol form.
  • Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.
  • Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990).
  • the amount of the compound in a formulation can vary within the full range employed by those skilled in the art.
  • the formulation will contain, on a weight percent (wt%) basis, from about 0.01-99.99 wt% of a compound of the present invention based on the total formulation, with the balance being one or more suitable pharmaceutical excipients.
  • the compound is present at a level of about 1-80 wt%. Representative pharmaceutical formulations are described below.
  • the present invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention in combination with a therapeutically effective amount of another active agent against RNA- dependent RNA virus and, in particular, against HCV.
  • Agents active against HCV include, but are not limited to, ribavirin, levovirin, viramidine, thymosin alpha- 1, an inhibitor of HCV NS3 serine protease, or an inhibitor of inosine monophosphate dehydrognease, interferon- ⁇ , pegylated interferon- ⁇ (peginterferon- ⁇ ), a combination of interferon- ⁇ and ribavirin, a combination of peginterferon- ⁇ and ribavirin, a combination of interferon- ⁇ and levovirin, and a combination of peginterferon- ⁇ and levovirin.
  • Interferon- ⁇ includes, but is not limited to, recombinant interferon- ⁇ 2a (such as ROFERON interferon available from Hoffman-LaRoche, Nutley, NJ), interferon- ⁇ 2b (such as Intron-A interferon available from Schering Corp., Kenilworth, New Jersey, USA), a consensus interferon, and a purified interferon- ⁇ product.
  • interferon- ⁇ 2a such as ROFERON interferon available from Hoffman-LaRoche, Nutley, NJ
  • interferon- ⁇ 2b such as Intron-A interferon available from Schering Corp., Kenilworth, New Jersey, USA
  • a consensus interferon such as Intron-A interferon available from Schering Corp., Kenilworth, New Jersey, USA
  • the agents active against hepatitis C virus also include agents that inhibit HCV proteases, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS 5 A protein, and inosine 5 '-monophosphate dehydrogenase.
  • Other agents include nucleoside analogs for the treatment of an HCV infection.
  • Still other compounds include those disclosed in WO 2004/014313 and WO 2004/014852 and in the references cited therein.
  • the patent applications WO 2004/014313 and WO 2004/014852 are hereby incorporated by references in their entirety.
  • Specific antiviral agents include Omega IFN (BioMedicines Inc.), BILN-2061 (Boehringer Ingelheim), Summetrel (Endo Pharmaceuticals Holdings Inc.), Roferon A (F. Hoffman-La Roche), Pegasys (F. Hoffman-La Roche), Pegasys/Ribaravin (F. Hoffrnan- La Roche), CellCept (F.
  • compositions and methods of the present invention contain a compound of formula 1 and interferon.
  • the interferon is selected from the group consisting of interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastiod interferon tau.
  • compositions and methods of the present invention contain a compound of formula 1 and a compound having anti-HCV activity is selected from the group consisting of interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'monophospate dehydrogenase inhibitor, amantadine, and rimantadine.
  • a compound having anti-HCV activity is selected from the group consisting of interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'monophospate dehydrogenase inhibitor, amantadine, and rimantadine.
  • Ingredient tablet mg compound of this invention 400 cornstarch 50 croscarmellose sodium 25 lactose 120 magnesium stearate 5
  • Formulation Example 2 Capsule formulation The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.
  • Ingredient Amount compound of this invention 1.0 g fumaric acid 0.5 g sodium chloride 2.0 g methyl paraben 0.15 g propyl paraben 0.05 g granulated sugar 25.0 g sorbitol (70% solution) 13.00 g Veegum K (Vanderbilt Co.) 1.0 g flavoring 0.035 mL colorings 0.5 mg distilled water q.s. to 100 mL Formulation Example 4 Injectable formulation
  • the following ingredients are mixed to form an injectable formulation.
  • a suppository of total weight 2.5 g is prepared by mixing the compound of the invention with Witepsol® H- 15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition: Ingredient Amount
  • DMEM Dulbeco's Modified Eagle's Medium
  • HATU O-(7-Azabenzotriazol- 1 -yl)-N, N, N 1 , N'- tetramethyluronium hexafluorophosphate
  • HBTU O-Benzotriazol-l-yl-N, N, N', N'- tetramethyluronium hexafluorophosphate
  • HCV hepatitus C virus
  • IPTG isopropyl- ⁇ -D-thiogalactopyranoside
  • IC 50 inhibitory concentration at 50% inhibition
  • NTA nitrilotriac ' etic acid
  • NTP nucleoside triphosphate
  • Tris Tris(hydroxymenthyl)aminomethane
  • Step 1 Synthesis of 1 -(4-Bromo- 1 H-pyrrol-2-yi)-2,2,2-trichloro-ethanone
  • 2,2,2-Tricliloro-l-(lH-pyrrol-2-yl)-ethanone 25g, 117.7mmol was dissolved in 500 niL carbon-tetrachloride. Iodine (88 mg) was added and the mixture was cooled to 0 C°. A solution of 6.03 mL bromine in 50 niL carbon tetrachloride was added dropwise over a period of 30 minutes. The stirring was continued for an additional 30 minutes at the same temperature then the reaction mixture was transferred to a separatory funnel and was washed successively with 100 mL of 10% Na 2 S 2 O 3 , saturated NaHCO 3 and brine (2x).
  • Step 3 Synthesis of 4-Bromo- l-tert-butoxycarbonylmethyl-lH-pyrrole-2-carboxylic acid methyl ester 4-Bromo- lH-pyrrole-2-carboxy lie acid methyl ester (4.9mmol) was dissolved in
  • Step 4 Synthesis of l-tert-Butoxycarbonylmethyl-4-cyclohexyl-lH-pyrrole-2-carboxylic acid methyl ester
  • 0.5M ZnCl 2 solution in THF was added 5.2mL 2M cyclohexyl- magnesium chloride at room temperature.
  • the mixture was stirred for 20 minutes then 15mL NMP was added and the stirring was continued for 5 more minutes.
  • 4-Bromo-l- tert-butoxycarbonylmethyl-lH-pyrrole-2-carboxylic acid methyl ester (1.095g, 3.44mmol) and 35mg Pd(P(tBu) 3 ) 2 were then added.
  • the mixture was heated at 100 0 C for 40 minutes.
  • Step 6 Synthesis of l-tert-Butoxycarbonylmethyl-4-cyclohexyl-5-[2-(2,4-dimethyl- thiazol-5-yl)-quinolin-6-yl]-lH-pyrrole-2-carboxylic acid methyl ester
  • a mixture of 5-brom.o- 1 -tert-butoxycarbonylmethyl-4-cyclohexyl- 1 H- ⁇ yrrole-2- carboxylic acid methyl ester (552mg, 1.3mmol), 2-(2,4-dimethyl-thiazol-5-yl)-quinoline- 6-boronic acid (522mg, 1.83mmol; below), tetrakis(triphenylphosphino)-palladium(0) (78mg, 0.07mmol), 26mL DMF, 26mL methanol, and 3.ImL saturated NaHCO 3 was heated at 80 0 C for Ih and then evaporated to dryness and purified on silica gel using hexan
  • a DMSO solution of the product bromide, potassium acetate (3 eq.) 5 P(Ph) 3 Pd(II)Cl 2 catalyst (.05 eq.) and bis(neopentylglycolato)diboron (3 eq.) was heated at 50 °C under argon for 4h. After 150 mL water and 150 mL ethyl acetate was added, the organic phase was separated. The aqueous phase was extracted one more time with 50 mL ethyl acetate. The organic phases were pooled and washed with water (2x) 5 brine (2x) and dried (sodium sulfate).
  • Step 7 Synthesis of l-Carboxymethyl-4-cyclohexyl-5-[2-(2,4-dimethyl-thiazol-5-yl)- quinolin-6-yl]-lH-pyrrole-2-carboxylic acid
  • Step 1 Synthesis of 4-Cyclohexyl-5-[2-(2,4-dimethyl-thiazol-5-yl)-quinolin-6-yl]-l-(2- morpholin-4-yl-2-oxo-ethyl)-lH-pyrrole-2-carboxylic acid methyl ester l-tert-Butoxycarbonylmethyl-4-cyclohexyl-5-[2-(2 5 4-dimethyl-thiazol-5-yl)- quinolin-6-yl]-lH-pyrrole-2-carboxylic acid methyl ester (514mg, 0.92mmol) was treated with a mixture of 2OmL TFA and 4mL anisole at room temperature for Ih.
  • Step 2 Synthesis of 4-Cyclohexyl-5-[2-(2,4-dimethyl-thiazol-5-yl)-quinolin-6-yl]-l-(2- morpholin-4-yl-2-oxo-ethyl)- 1 H-pyrrole-2-carboxylic acid
  • Compounds can exhibit anti-hepatitis C activity by inhibiting HCV polymerase, by inhibiting other enzymes needed in the replication cycle, or by other pathways.
  • a number of assays have been published to assess these activities.
  • a general method that assesses the gross increase of HCV virus in culture is disclosed in U.S. Patent No. 5,738,985 to Miles et al
  • In vitro assays have been reported in Ferrari et al JnI. ofVir., 73:1649-1654, 1999; Isf ⁇ i et al, Hepatology, 29:1227-1235, 1999; Lohmann et al, JnI of Bio. Chem., 274:10807-10815, 1999; and Yamashita et al, JnI of Bio. Chem., 273:15479-15486, 1998.
  • HCV polymerase assay that can be used to evaluate the activity of the of the compounds described herein.
  • Another HCV polymerase assay has been reported by Bartholomeusz, et al, Hepatitis C Virus (HCV) RNA polymerase assay using cloned HCV non-structural proteins; Antiviral Therapy 1996:l(Sup ⁇ 4) 18-24.
  • Example 2 Replicon Assay A cell line, ET (Huh-lucubineo-ET) was used for screening of compounds of the present invention for HCV RNA dependent RNA polymerase.
  • the ET cell line was stably transfected with RNA transcripts harboring a l 389 luc-ubi-neo/NS3-37ET; replicon with firefly luciferase-ubiquitin-neomycin phosphotransferase fusion protein and EMCV-IRES driven NS3-5B polyprotein containing the cell culture adaptive mutations (E1202G; T1280I; Kl 846T) (Krieger at al, 2001 and unpublished).
  • the ET cells were grown in DMEM, supplemented with 10% fetal calf serum, 2 mM Glutamine, Penicillin (100 IU/mL)/Streptomycin (100 ⁇ g/mL), Ix nonessential amino acids, and 250 ⁇ g/mL G418 ("Geneticin"). They were all available through Life Technologies (Bethesda, MD). The cells were plated at 0.5-1.0 xlO 4 cells/well in the 96 well plates and incubated for 24 hrs before adding nucleoside analogs. Then the compounds were added to the cells to achieve a final concentration of 5 or 50 ⁇ M.
  • % Inhibition 100 — [100*(Lum with inhibitor-bg)/(Lum with no inhibitor-bg)] where bg was the background with no replicon cell, and Lum was the luminescence intensity of the reporter luciferase gene.
  • the cloned fragment is missing the C terminus 21 amino acid residues.
  • the cloned fragment is inserted into an IPTG-induc ⁇ ble expression plasmid that provides an epitope tag (His)6 at the carboxy terminus of the protein.
  • the recombinant enzyme is expressed in XL-I cells and after induction of expression, the protein is purified using affinity chromatography on a nickel-NTA column. Storage condition is 10 mM Tris-HCl pH 7.5, 50 mM NaCl, 0.1 mM EDTA 5 1 mM DTT, 20% glycerol at -20 °C.
  • the polymerase activity is assayed by measuring incorporation of radiolabeled UTP into a RNA product using a biotinylated, heteropolymeric template, which includes a portion of the HCV genome.
  • the assay mixture (50 ⁇ L) contains 10 mM Tris-HCl (pH 7.5), 5 mM MgCl 2 , 0.2 mM EDTA, 10 mM KCl, 1 unit/ ⁇ t RNAsin, 1 mM DTT, 10 ⁇ M each of NTP, including [ 3 H]-UTP, and 10 ng/ ⁇ L heteropolymeric template.
  • Test compounds are initially dissolved in 100% DMSO and further diluted in aqueous buffer containing 5% DMSO.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés, des compositions et des méthodes de traitement des infeeections par un virus de la famille des Flaviviridae.
PCT/US2006/024554 2005-06-24 2006-06-22 Derives d'heteroaryle utilises dans le traitement des virus WO2006138744A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002613261A CA2613261A1 (fr) 2005-06-24 2006-06-22 Derives d'heteroaryle utilises dans le traitement des virus
AU2006261132A AU2006261132A1 (en) 2005-06-24 2006-06-22 Heteroaryl derivatives for treating viruses
EP06799960A EP1910337A2 (fr) 2005-06-24 2006-06-22 Derives d'heteroaryle utilises dans le traitement des virus
BRPI0612124-1A BRPI0612124A2 (pt) 2005-06-24 2006-06-22 derivados de heteroarila para o tratamento de viroses
JP2008518457A JP2008546802A (ja) 2005-06-24 2006-06-22 ウイルスを治療するためのヘテロアリール誘導体
MX2007016144A MX2007016144A (es) 2005-06-24 2006-06-22 Derivados de heteroaril para tratar virus.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69370005P 2005-06-24 2005-06-24
US60/693,700 2005-06-24

Publications (2)

Publication Number Publication Date
WO2006138744A2 true WO2006138744A2 (fr) 2006-12-28
WO2006138744A3 WO2006138744A3 (fr) 2007-04-05

Family

ID=37499598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/024554 WO2006138744A2 (fr) 2005-06-24 2006-06-22 Derives d'heteroaryle utilises dans le traitement des virus

Country Status (14)

Country Link
US (1) US20060293320A1 (fr)
EP (1) EP1910337A2 (fr)
JP (1) JP2008546802A (fr)
KR (1) KR20080040677A (fr)
CN (1) CN101223161A (fr)
AR (1) AR054797A1 (fr)
AU (1) AU2006261132A1 (fr)
BR (1) BRPI0612124A2 (fr)
CA (1) CA2613261A1 (fr)
MA (1) MA28394B1 (fr)
MX (1) MX2007016144A (fr)
PE (1) PE20070124A1 (fr)
TW (1) TW200726471A (fr)
WO (1) WO2006138744A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2494991A1 (fr) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Polythérapie pour le traitement de l'infection par VHC

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1996233A2 (fr) * 2006-02-27 2008-12-03 Gilead Colorado, Inc. Combinaisons thérapeutiques et méthodes pour amélioration cardio-vasculaire et traitement de maladie cardio-vasculaire
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2009002534A1 (fr) * 2007-06-26 2008-12-31 Gilead Colorado, Inc. Inhibiteurs d'imidazopyridinyl-thiazolyl-histone désacétylase
WO2010009139A2 (fr) * 2008-07-14 2010-01-21 Gilead Colorado, Inc. Composés inhibiteurs de pyrimidine imidazolyle
US8344018B2 (en) * 2008-07-14 2013-01-01 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
AU2009271019A1 (en) * 2008-07-14 2010-01-21 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
MX2011001090A (es) * 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
DK2315590T3 (da) * 2008-08-15 2012-11-19 N30 Pharmaceuticals Inc Pyrrolinhibitorer af S-nitrosoglutathionreduktase
EP2318007B1 (fr) 2008-08-15 2013-01-23 N30 Pharmaceuticals, Inc. Nouveaux inhibiteurs pyrrole de s-nitrosoglutathione réductase en tant qu'agents thérapeutiques
EP3069721A1 (fr) 2008-08-15 2016-09-21 Nivalis Therapeutics, Inc. Nouveaux inhibiteurs pyrroliques de s-nitrosoglutathion réductase en tant qu'agents thérapeutiques
PE20120003A1 (es) 2009-01-30 2012-02-12 Glaxosmithkline Llc Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil)etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino
MX2011013166A (es) * 2009-06-08 2012-01-30 Gilead Sciences Inc Compuestos inhibidores de hdac de cicloalquilcarbamatobenzamida-an ilina.
EP2440519A1 (fr) * 2009-06-08 2012-04-18 Gilead Sciences, Inc. Composés inhibiteurs d'hdac à base d'alkanoylamino benzamide aniline
EP2337781B1 (fr) * 2009-06-11 2014-07-23 AbbVie Bahamas Ltd. Composés antiviraux pour le traitement d'infections hcv
US8822515B2 (en) 2009-10-16 2014-09-02 University Of Maryland, Baltimore County Heterocyclic benzoxazole compositions as inhibitors of hepatitis C virus
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
TWI508968B (zh) * 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
MX2013003060A (es) * 2010-09-30 2013-05-30 Boehringer Ingelheim Int Terapia de combinacion para tratar infeccion por hcv.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010140A2 (fr) * 2001-07-25 2003-02-06 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de polymerase virale
WO2004087714A1 (fr) * 2003-04-04 2004-10-14 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Acetamides d'indole comme inhibiteurs de la polymerase ns5b du virus de l'hepatite c
WO2005012288A1 (fr) * 2003-08-01 2005-02-10 Genelabs Technologies, Inc Derives de l'imidazole bicycliques diriges contre les flaviviridae

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
AU7675491A (en) * 1990-04-04 1991-10-30 Chiron Corporation Hepatitis c virus protease
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5738985A (en) * 1993-04-02 1998-04-14 Ribogene, Inc. Method for selective inactivation of viral replication
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
US5759795A (en) * 1996-03-08 1998-06-02 Schering Corporation Assay for determining inhibitors of ATPase
CA2283379A1 (fr) * 1997-03-05 1998-09-11 Michael G. Katze Nouveaux procedes de criblage permettant l'identification d'agents inhibant de maniere selective la replication du virus de l'hepatite c
WO1999029843A1 (fr) * 1997-12-11 1999-06-17 Smithkline Beecham Corporation Proteine tronquee du virus ns5b de l'hepatite c et procedes associes d'identification de composes antiviraux
AR029803A1 (es) * 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
PL375442A1 (en) * 2002-07-18 2005-11-28 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010140A2 (fr) * 2001-07-25 2003-02-06 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de polymerase virale
WO2004087714A1 (fr) * 2003-04-04 2004-10-14 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Acetamides d'indole comme inhibiteurs de la polymerase ns5b du virus de l'hepatite c
WO2005012288A1 (fr) * 2003-08-01 2005-02-10 Genelabs Technologies, Inc Derives de l'imidazole bicycliques diriges contre les flaviviridae

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2494991A1 (fr) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Polythérapie pour le traitement de l'infection par VHC

Also Published As

Publication number Publication date
AU2006261132A1 (en) 2006-12-28
CN101223161A (zh) 2008-07-16
JP2008546802A (ja) 2008-12-25
US20060293320A1 (en) 2006-12-28
KR20080040677A (ko) 2008-05-08
MA28394B1 (fr) 2007-01-02
MX2007016144A (es) 2008-03-06
TW200726471A (en) 2007-07-16
BRPI0612124A2 (pt) 2010-10-19
CA2613261A1 (fr) 2006-12-28
EP1910337A2 (fr) 2008-04-16
AR054797A1 (es) 2007-07-18
WO2006138744A3 (fr) 2007-04-05
PE20070124A1 (es) 2007-03-09

Similar Documents

Publication Publication Date Title
WO2006138744A2 (fr) Derives d'heteroaryle utilises dans le traitement des virus
US20070032488A1 (en) 6-Membered aryl and heteroaryl derivatives for treating viruses
EP1844042A1 (fr) Derives d'indole pour le traitement d'infections virales
US20080193411A1 (en) Anti-viral Compounds
US20090317360A1 (en) Anti-viral inhibitors and methods of use
EP2044083A1 (fr) Agents antiviraux
BRPI0619733A2 (pt) compostos antivirais de n-(anel aromático de 6 membros)-amido
EP2049536A2 (fr) Inhibiteurs viraux polycycliques
US20100061960A1 (en) Amido Anti-Viral Compounds, Compositions, And Methods Of Use
US20080051384A1 (en) Antiviral agents
WO2010081149A1 (fr) Composés antiviraux, compositions et méthodes d'application

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680026216.9

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/016144

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2008518457

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2613261

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006261132

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 50/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006799960

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020087001748

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008102157

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2006261132

Country of ref document: AU

Date of ref document: 20060622

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06799960

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0612124

Country of ref document: BR

Kind code of ref document: A2